Trial Profile
A phase II study of carboplatin and amrubicin with a biweekly schedule in patients with advanced squamous cell lung cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Carboplatin (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jan 2015 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
- 20 Jan 2012 New trial record